Cholinergic Agonists & Anticholinesterases — Cholinergic agonists and anticholinesterases: core effects and uses - Pharmacology

SECTION 1

Historical Context & Motivation

The story of cholinergic pharmacology begins with the recognition that the nervous system communicates with target organs through chemical messengers rather than purely electrical impulses. In the early twentieth century, physiologists debated whether nerve signals crossed the synapse electrically or chemically, and the resolution of this debate laid the groundwork for modern autonomic pharmacology. The identification of acetylcholine (ACh) as the first confirmed neurotransmitter not only settled the debate but also opened an entirely new therapeutic landscape—one in which drugs could be designed to either mimic ACh at its receptors or prevent its enzymatic destruction by acetylcholinesterase (AChE).

1914 • Dale Characterizes Acetylcholine Actions

Henry Dale demonstrated that acetylcholine could reproduce the effects of parasympathetic nerve stimulation on smooth muscle and glands, distinguishing muscarinic from nicotinic actions using the alkaloids muscarine and nicotine.

1921 • Loewi Proves Chemical Neurotransmission

Otto Loewi's elegant frog-heart experiment showed that vagus-nerve stimulation released a 'Vagusstoff' (later identified as ACh) that could slow a second, denervated heart—providing definitive proof of chemical synaptic transmission.

1934 • Physostigmine Enters Clinical Use

Physostigmine, an alkaloid from the Calabar bean long used in West African ordeal trials, was purified and deployed clinically for glaucoma, establishing the therapeutic principle of acetylcholinesterase inhibition.

1993 • Tacrine Approved for Alzheimer Disease

The FDA approval of tacrine marked the first cholinesterase inhibitor indicated for Alzheimer disease, validating the cholinergic hypothesis of cognitive decline and catalyzing development of donepezil, rivastigmine, and galantamine.

2000s • Selective Muscarinic Agonists & Novel AChE Inhibitors

Ongoing research targets subtype-selective muscarinic agonists (e.g., M₁ and M₃ selective agents) and dual-mechanism AChE inhibitors, aiming to minimize side effects while preserving efficacy in neurodegenerative and urologic disorders.

These milestones reveal a central question that drives this lesson: How can we therapeutically harness cholinergic signaling—either by directly activating ACh receptors or by blocking the enzyme that degrades ACh—while managing the inevitable systemic effects that arise from the ubiquity of cholinergic transmission? Answering that question requires a firm grasp of receptor subtypes, drug classifications, organ-level pharmacodynamics, and clinical indications.

SECTION 2

Core Principles & Definitions

To understand cholinergic agonists and anticholinesterases, you must first appreciate the framework of cholinergic neurotransmission itself. Acetylcholine is synthesized in the nerve terminal from choline and acetyl-CoA by the enzyme choline acetyltransferase (ChAT). Once released into the synaptic cleft, ACh binds postsynaptic muscarinic or nicotinic receptors and is then rapidly hydrolyzed by AChE into choline (which is recycled) and acetate. Drugs in this chapter either act as direct-acting agonists at cholinergic receptors or as indirect-acting agents (anticholinesterases) that elevate endogenous ACh by inhibiting its breakdown.

Muscarinic Receptors (M₁–M₅)

G-protein–coupled receptors found at parasympathetic neuroeffector junctions. M₁ (neural), M₂ (cardiac), and M₃ (glandular/smooth muscle) are the most clinically relevant subtypes. Odd-numbered subtypes (M₁, M₃, M₅) couple to G_q and activate phospholipase C; even-numbered subtypes (M₂, M₄) couple to G_i and decrease cAMP.

Nicotinic Receptors ( $N_N$ & $N_M$ )

Ligand-gated ion channels permeable to Na⁺ and K⁺. N_N (neuronal) receptors reside at autonomic ganglia and the CNS; N_M (muscle) receptors are at the neuromuscular junction. Stimulation produces fast depolarization and excitation.

Direct-Acting Cholinergic Agonists

Drugs such as bethanechol, carbachol, pilocarpine, and methacholine bind directly to muscarinic or nicotinic receptors, mimicking ACh but resisting hydrolysis by AChE.

Anticholinesterases (Indirect Agonists)

These agents—neostigmine, physostigmine, donepezil, and organophosphates—inhibit AChE and thereby increase ACh concentration at all cholinergic synapses, amplifying both muscarinic and nicotinic effects.

The SLUDGE/DUMBBELSS Mnemonic

Excess muscarinic stimulation manifests as DUMBBELSS: Diarrhea, Urination, Miosis, Bradycardia, Bronchospasm, Emesis, Lacrimation, Salivation, Sweating. This mnemonic is indispensable when predicting side effects or recognizing cholinergic toxicity.

✦

KEY TAKEAWAY

Think of ACh as water flowing through a pipe. A direct cholinergic agonist is like opening a second faucet that pours the same kind of water into the basin—it adds more signal regardless of what the original nerve is doing. An anticholinesterase is like plugging the drain so that whatever water the faucet releases accumulates faster. Both strategies flood the basin, but the anticholinesterase depends on the nerve still running the faucet—endogenous ACh must be present for the drug to work.

SECTION 3

Cholinergic Synapse — Visual Overview

The diagram shows the cholinergic synapse from presynaptic synthesis of ACh through exocytotic release, receptor binding (muscarinic and nicotinic), and enzymatic degradation by AChE. Direct agonists activate postsynaptic receptors, while anticholinesterases block AChE in the cleft, allowing endogenous ACh to accumulate and exert prolonged effects.

The diagram above captures the two fundamental pharmacological strategies in cholinergic therapeutics. In the upper portion, ACh is synthesized and packaged into vesicles, then released into the cleft upon nerve depolarization. On the postsynaptic membrane, both muscarinic (GPCR) receptors and nicotinic (ion-channel) receptors transduce the signal. AChE in the cleft normally terminates signaling within milliseconds. A direct agonist such as bethanechol bypasses the presynaptic machinery entirely and activates receptors on its own, whereas an anticholinesterase like neostigmine blocks the enzymatic step, causing endogenous ACh to linger and intensify its effects at every cholinergic site—muscarinic, nicotinic, and central (if the drug crosses the blood–brain barrier).

SECTION 4

Mechanisms of Action — Direct vs. Indirect

Direct-Acting Cholinergic Agonists

Direct-acting cholinergic agonists are structural analogs of ACh that bind to muscarinic receptors, nicotinic receptors, or both. The key molecular modification shared by most clinically useful agents is resistance to hydrolysis by AChE. For example, bethanechol is a carbamyl ester of β-methylcholine; the carbamyl group and β-methyl substitution render it virtually impervious to AChE and confer selectivity for muscarinic (especially M₃) receptors with negligible nicotinic activity. Clinically, bethanechol is used to stimulate the detrusor muscle in postoperative or neurogenic urinary retention. Carbachol, by contrast, retains both muscarinic and nicotinic activity because of its unsubstituted choline backbone, making it useful for intraocular application in glaucoma where miosis is desired.

Pilocarpine is a naturally occurring alkaloid that acts as a partial muscarinic agonist. It is lipophilic enough to penetrate the cornea, making it a mainstay for treating acute angle-closure glaucoma (via ciliary muscle contraction and pupillary constriction that opens the trabecular meshwork). It is also administered orally for xerostomia (dry mouth) in Sjögren syndrome or following radiation therapy to the head and neck. Methacholine is primarily used in bronchial provocation testing: because asthmatic airways are hyperreactive, inhalation of methacholine at low doses triggers bronchoconstriction and confirms a diagnosis of airway hyperresponsiveness.

Indirect-Acting Agents — Anticholinesterases

Anticholinesterases inhibit AChE, the enzyme responsible for hydrolyzing ACh into choline and acetate. By doing so, they increase the concentration and duration of action of endogenous ACh at all cholinergic synapses. These drugs are classified by the reversibility and duration of their interaction with the enzyme's active site.

Reversible (short-acting): Edrophonium forms an electrostatic and hydrogen-bond complex at the anionic and esteratic sites of AChE, lasting only 2–10 minutes. Historically used in the Tensilon test for myasthenia gravis diagnosis.
Reversible (intermediate-acting): Neostigmine, pyridostigmine, and physostigmine form a carbamylated enzyme intermediate that hydrolyzes over 30 minutes to 6 hours. These are the workhorses for myasthenia gravis treatment, reversal of neuromuscular blockade, and antidote use in anticholinergic poisoning.
Irreversible: Organophosphates (e.g., sarin, malathion, parathion) phosphorylate the serine hydroxyl at the esteratic site. The covalent bond 'ages' and becomes resistant to reactivation, producing long-lasting toxicity requiring pralidoxime (2-PAM) and atropine for treatment.

⚠

Clinical Pearl — Aging of Organophosphates

Pralidoxime (2-PAM) can reactivate phosphorylated AChE only before the phosphoryl-enzyme complex undergoes aging (loss of an alkyl group that stabilizes the covalent bond). The window varies by agent—soman ages in minutes, whereas malathion's window extends to hours. Early administration is therefore critical.

SECTION 5

Drug Classification & Organ-Level Effects

The effects of cholinergic agonists and anticholinesterases can be predicted by understanding which organ systems receive parasympathetic (cholinergic) innervation and the receptor subtypes involved. The following table organizes these effects by organ system, receptor subtype, and expected response when cholinergic tone is increased.

Organ System	Receptor	Effect of ↑ Cholinergic Tone	Clinical Relevance
Eye	M₃ (iris sphincter, ciliary muscle)	Miosis, ↓ intraocular pressure, accommodation for near vision	Glaucoma (pilocarpine, carbachol)
Heart	M₂ (SA node, AV node)	↓ Heart rate (negative chronotropy), ↓ AV conduction velocity	Bradycardia is a key side effect; used diagnostically (methacholine)
Lungs	M₃ (bronchial smooth muscle, glands)	Bronchoconstriction, ↑ secretions	Contraindicated in asthma/COPD; methacholine provocation test
GI Tract	M₃ (smooth muscle, glands)	↑ Motility, ↑ secretions, relaxation of sphincters	Bethanechol for postoperative ileus
Bladder	M₃ (detrusor muscle)	Contraction of detrusor, relaxation of trigone & sphincter → voiding	Bethanechol for urinary retention
Glands	M₃ (salivary, lacrimal, sweat)	↑ Salivation, lacrimation, sweating	Pilocarpine for xerostomia (Sjögren)
Skeletal Muscle	$N_M$ (NMJ)	Maintained depolarization → contraction (at therapeutic doses); depolarizing block at excess doses	Neostigmine/pyridostigmine for myasthenia gravis; reversal of NMJ blockade
CNS	M₁ (cortex, hippocampus)	↑ Cognitive function, arousal	Donepezil, rivastigmine, galantamine for Alzheimer disease

Organ-Level Effects of Increased Cholinergic Tone

This classification tree divides cholinomimetics into direct agonists (choline esters and alkaloids) and indirect agents (anticholinesterases) organized by reversibility and duration. Receptor selectivity is noted in parentheses.

SECTION 6

Worked Example — Clinical Reasoning with Cholinomimetics

A 68-year-old woman with recently diagnosed myasthenia gravis presents with ptosis and fatigable proximal limb weakness. Her neurologist initiates therapy with pyridostigmine 60 mg orally three times daily. Walk through the pharmacological reasoning for this choice and predict both the therapeutic and adverse effects.

Why Pyridostigmine for Myasthenia Gravis?

1
Step 1 — Identify the Pathophysiology

Myasthenia gravis is an autoimmune disorder in which antibodies (most commonly anti-AChR antibodies) attack nicotinic receptors at the neuromuscular junction (N_M). This reduces the number of functional receptors, so each quantum of ACh released by the motor neuron produces a smaller end-plate potential, eventually failing to reach threshold and causing fatigable weakness.

Reduced functional N_M receptors → decreased safety margin for neuromuscular transmission.
2
Step 2 — Select the Drug Class

The goal is to maximize the effect of the ACh that is still being released. An anticholinesterase inhibitor prevents AChE from degrading ACh, thereby increasing its synaptic concentration and duration. This compensates for the reduced receptor density. A direct nicotinic agonist would be less desirable because it could cause sustained depolarization and desensitization of the remaining receptors.

Anticholinesterase is the preferred class—indirect enhancement of endogenous ACh.
3
Step 3 — Choose the Specific Agent

Pyridostigmine is favored over neostigmine for chronic oral therapy because it has a longer duration of action (3–6 hours vs. 2–4 hours), smoother plasma levels, and fewer muscarinic side effects. Unlike physostigmine, pyridostigmine carries a quaternary ammonium group and therefore does not cross the blood–brain barrier—this avoids CNS side effects such as seizures or central cholinergic toxicity.

Pyridostigmine: oral, intermediate-acting, poor CNS penetration—ideal for chronic management.
4
Step 4 — Predict Therapeutic Effects

By raising ACh concentration at the NMJ, pyridostigmine increases end-plate potential amplitude. The patient should experience improved muscle strength, reduced ptosis, and better exercise tolerance. Peak effect occurs roughly 1–2 hours post-dose, so timing with meals prevents dysphagia.

Expected: ↑ skeletal muscle strength, ↓ fatigability, resolution of ptosis
5
Step 5 — Anticipate Adverse Effects

Because anticholinesterases raise ACh at all cholinergic synapses, muscarinic side effects are expected: increased salivation, diarrhea, abdominal cramping, miosis, and bradycardia (recall DUMBBELSS). These can be managed with concurrent low-dose atropine or glycopyrrolate. Overdose can produce a cholinergic crisis (excessive ACh at the NMJ causes depolarization block → paradoxical worsening of weakness), which must be distinguished from a myasthenic crisis.

Muscarinic ADRs managed with atropine; monitor for cholinergic crisis vs. myasthenic crisis.

SECTION 7

Comparing Direct Agonists & Anticholinesterases

While both direct-acting agonists and anticholinesterases ultimately increase cholinergic activity, they differ fundamentally in receptor dependence, selectivity, and clinical deployment. The following table highlights these contrasts and can serve as a high-yield comparison for clinical decision-making.

Feature	Direct Agonists	Anticholinesterases
Mechanism	Bind and activate muscarinic and/or nicotinic receptors directly	Inhibit AChE → ↑ endogenous ACh at all cholinergic synapses
Dependence on Intact Nerve	No — works even on denervated tissue	Yes — requires ongoing ACh release from presynaptic neuron
Receptor Selectivity	Can be designed for muscarinic only (bethanechol) or both (carbachol)	Non-selective; amplifies ACh at muscarinic, nicotinic, and CNS synapses
Side-Effect Profile	More predictable—limited to the receptor type targeted	Broader—muscarinic + nicotinic + CNS effects possible
Primary Clinical Uses	Glaucoma, urinary retention, xerostomia, bronchoprovocation testing	Myasthenia gravis, Alzheimer disease, reversal of NMJ blockade, glaucoma, anticholinergic poisoning
Example Prototypes	Bethanechol, pilocarpine, carbachol, methacholine	Neostigmine, pyridostigmine, physostigmine, donepezil, organophosphates

Direct Agonists vs. Anticholinesterases — Key Differences

✦

KEY TAKEAWAY

Choosing between a direct agonist and an anticholinesterase is analogous to choosing between adding more fuel to a furnace versus closing the chimney flue. A direct agonist delivers its own 'fuel' regardless of whether the furnace is running. An anticholinesterase traps the heat already being generated, which means it only works if the furnace (the nerve) is actively producing ACh. In myasthenia gravis, the nerve works fine—it's the receptor that's diminished—so trapping more ACh (closing the flue) makes physiological sense. In a denervated bladder, however, no ACh is being released, and you must supply the agonist directly.

SECTION 8

Connections to Advanced Pharmacology & Toxicology

Mastering the cholinergic agonist and anticholinesterase pharmacology in this lesson creates a foundation for several advanced topics you will encounter in clinical rotations, toxicology electives, and board examinations. These include organophosphate and nerve-agent toxicology, the management of cholinergic and myasthenic crises, the cholinergic hypothesis of Alzheimer disease, and the rapidly evolving field of subtype-selective muscarinic modulation for neuropsychiatric indications.

This Lesson (Foundation)	Advanced Extension
DUMBBELSS mnemonic for muscarinic excess	Full toxidrome differentiation: cholinergic vs. anticholinergic vs. sympathomimetic
Reversible vs. irreversible AChE inhibition	Organophosphate poisoning management: atropine titration, pralidoxime window, MARK-1 autoinjector protocols
Donepezil for Alzheimer disease	Cholinergic hypothesis: relationship between basal nucleus of Meynert degeneration and cortical ACh deficit; combination therapy with memantine (NMDA antagonist)
Neostigmine for reversal of NMJ blockade	Sugammadex as a novel encapsulation-based reversal agent; comparison of neostigmine + glycopyrrolate vs. sugammadex in anesthesia practice
Cholinergic crisis vs. myasthenic crisis	Edrophonium (Tensilon) test interpretation; ice-pack test; serologic and electrophysiologic diagnosis of MG subtypes

From Foundations to Advanced Topics

Looking ahead, current research aims to develop M₁-selective positive allosteric modulators that could enhance cognition in Alzheimer disease without triggering widespread M₂ and M₃-mediated side effects. Similarly, peripherally restricted butyrylcholinesterase inhibitors are being investigated for their potential to improve gastrointestinal motility without CNS penetration. Understanding the principles in this lesson—receptor subtype selectivity, enzyme kinetics of AChE inhibition, and organ-level pharmacodynamics—provides the conceptual toolkit needed to evaluate these next-generation therapeutics.

SECTION 9

Practice Problems

Question 1: CONCEPTUAL

A patient with denervated bladder smooth muscle (e.g., following spinal cord injury with lower motor neuron lesion) needs pharmacological assistance to void. Would an anticholinesterase such as neostigmine be effective in this scenario? Why or why not? Which class of drug would be more appropriate?

Show answer

Neostigmine would be ineffective because anticholinesterases work by preventing the breakdown of endogenous ACh—they require intact presynaptic nerve terminals that are actively releasing ACh. In a denervated bladder, there is no cholinergic nerve input, so there is no ACh to preserve. A direct-acting muscarinic agonist such as bethanechol would be more appropriate because it directly activates M₃ receptors on the detrusor muscle independent of nerve function. This distinction between 'adding more signal' (direct agonist) and 'preserving existing signal' (anticholinesterase) is the foundational concept separating the two drug classes.

Question 2: BASIC CALCULATION

Pyridostigmine has a half-life of approximately 1.5 hours. If a patient takes a 60 mg dose, approximately how much drug remains in the body after 6 hours, assuming first-order elimination and complete absorption? Express your answer to the nearest milligram.

Show answer

Using the first-order decay equation: Amount remaining = Dose × (1/2)^(t/t½). Here t = 6 hours and t½ = 1.5 hours, so the number of half-lives = 6 ÷ 1.5 = 4. Amount remaining = 60 × (1/2)⁴ = 60 × 1/16 = 3.75 mg ≈ 4 mg. This calculation illustrates why pyridostigmine must be dosed three to four times daily to maintain therapeutic ACh levels at the neuromuscular junction, and why patients notice fluctuating muscle strength between doses.

Question 3: INTERMEDIATE

A patient on chronic pyridostigmine therapy for myasthenia gravis develops sudden worsening of weakness, excessive salivation, diarrhea, and miosis. Is this a cholinergic crisis or a myasthenic crisis? What would be the next diagnostic and therapeutic step?

Show answer

The combination of worsening weakness with prominent muscarinic signs (salivation, diarrhea, miosis) strongly suggests a cholinergic crisis—excessive ACh at the NMJ causing depolarization block (phase II block) and simultaneously overstimulating muscarinic receptors. A myasthenic crisis, by contrast, presents with weakness but lacks muscarinic excess symptoms. Historically, the edrophonium (Tensilon) test was used diagnostically: a small IV dose of edrophonium would transiently improve a myasthenic crisis but worsen a cholinergic crisis. Due to risks, many clinicians now prefer clinical assessment and EMG. The therapeutic step in cholinergic crisis is to withhold pyridostigmine, administer atropine to manage muscarinic symptoms, and provide ventilatory support as needed.

Question 4: APPLIED

A farmer is brought to the emergency department with pinpoint pupils, profuse salivation, wheezing, muscle fasciculations, and altered mental status after working with insecticides. Serum and red blood cell cholinesterase levels are markedly depressed. Outline the pharmacological management of this patient, explaining the rationale for each drug chosen.

Show answer

This presentation is classic for organophosphate poisoning—an irreversible inhibition of AChE causing excess ACh at all cholinergic synapses. Management requires a two-pronged pharmacological approach. First, atropine (a muscarinic antagonist) is administered IV and titrated to dry secretions; it blocks muscarinic effects (bronchospasm, bradycardia, salivation) but does not address nicotinic symptoms (fasciculations, weakness). Second, pralidoxime (2-PAM) is given as early as possible to reactivate phosphorylated AChE before the enzyme-phosphoryl complex 'ages' (undergoes dealkylation that makes the bond permanent). Pralidoxime addresses both muscarinic and nicotinic toxicity at the enzymatic level. Benzodiazepines (e.g., diazepam) may be added for organophosphate-induced seizures. Decontamination (removal of clothing, skin washing) is also essential to prevent continued absorption.

Question 5: CRITICAL THINKING

Physostigmine crosses the blood–brain barrier, whereas neostigmine does not. Both are reversible anticholinesterases. Discuss how this difference in CNS penetration influences their respective clinical indications, contraindications, and side-effect profiles. Under what clinical circumstances would you specifically choose physostigmine over neostigmine, and why?

Show answer

The critical structural difference is that physostigmine is a tertiary amine (uncharged at physiologic pH, lipophilic), while neostigmine is a quaternary ammonium compound (permanently charged, hydrophilic). Because physostigmine crosses the BBB, it can reverse central anticholinergic toxicity—making it the agent of choice for treating delirium or coma caused by overdose of anticholinergic drugs such as atropine, diphenhydramine, or tricyclic antidepressants (though TCAs carry cardiac risk with physostigmine). Neostigmine, confined to the periphery, cannot address central symptoms and is therefore preferred for purely peripheral indications: myasthenia gravis, reversal of non-depolarizing neuromuscular blockade, and postoperative ileus/urinary retention. The downside of physostigmine's CNS access is that it can itself cause central cholinergic side effects—seizures, bradycardia via vagal nuclei stimulation—making careful dose titration essential. In summary, the BBB-crossing ability of physostigmine is both its therapeutic advantage (central anticholinergic poisoning) and its liability (CNS side effects), whereas neostigmine's exclusion from the CNS limits its toxicity profile but restricts its utility to peripheral cholinergic enhancement.

SUMMARY

Lesson Summary

Summary

Cholinergic agonists are drugs that increase cholinergic transmission either by directly binding muscarinic and/or nicotinic receptors (direct agonists: bethanechol, carbachol, pilocarpine, methacholine) or by inhibiting acetylcholinesterase (AChE) to raise endogenous ACh levels (indirect agonists / anticholinesterases: neostigmine, pyridostigmine, physostigmine, donepezil, organophosphates). Direct agonists work independently of intact innervation and can be designed with receptor-subtype selectivity, while anticholinesterases depend on ongoing presynaptic ACh release and amplify effects at all cholinergic synapses.

The organ-level effects of increased cholinergic tone are captured by the DUMBBELSS mnemonic and include miosis, bradycardia, bronchoconstriction, increased GI and bladder motility, and glandular hypersecretion. Key clinical applications span glaucoma (pilocarpine), urinary retention (bethanechol), myasthenia gravis (pyridostigmine), Alzheimer disease (donepezil), and reversal of neuromuscular blockade (neostigmine). Anticholinesterase duration ranges from minutes (edrophonium) to hours (pyridostigmine) to permanent (organophosphates), with irreversible inhibitors requiring emergent treatment with atropine and pralidoxime before enzymatic aging renders reactivation impossible.